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This report, produced by the drug checking service of the City of Zurich, 
Switzerland, describes data collected by the service between 
January and August 2020. 
The original publication in German can be consulted at 
https://saferparty.ch/tl_files/images/download/file/aktuelles%202020/
Synthetische%20Cannabinoide%20Auswertung%20August%202020.pdf
The service plans to publish the next report in January 2021.
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 Ǳ In 2019, synthetic cannabinoids were tested for the first time as an additive in 
cannabis flowers or hashish in various Swiss drug-checking offers.
 Ǳ Since the beginning of 2020, the Drug Information Centre (DIZ) of the City of 
Zürich has been increasingly analysing cannabis samples which users believed 
that had been treated with synthetic cannabinoids.
 Ǳ Synthetic cannabinoids were found in more than half (50 of 91) of the samples in 
the course of laboratory analyses.
 Ǳ Synthetic cannabinoids are largely unexplored and are suspected of causing 
severe side effects and even death.
 Ǳ The assessment that cannabis is a substance with a comparatively low risk of 
overdose has been obsolete since the appearance of synthetic cannabinoids.
 Ǳ The DIZ advises all cannabis users to exercise caution and adhere to the rules 
of safer use when consuming.
 Ǳ From October 1, 2020, a total of 10 cannabis samples can be handed in at the 
DIZ weekly.
The term “synthetic cannabinoids” has established itself internationally for this 
group of substances. However, it is not selective, because cannabinoids, which are 
naturally formed in the hemp plant and have a significantly lower risk potential 
(THC and CBD), can also be synthetically produced. The group known as synthetic 
cannabinoids is similar in its mechanism of action to THC, the psychoactive 
ingredient in cannabis. This group binds to the same receptors (CB1 / CB2) as THC, 
but with a partly more than 100 times stronger bond, which explains its significantly 
more intense effect. Synthetic cannabinoids thus imitate the effects of THC yet 
differ in their structure 1. Because of their mechanism of action, they are also referred 
to as cannabimimetic (mimicking = imitating) or cannabinoid receptor agonists.
THE ESSENTIALS IN BRIEF
WHAT ARE SYNTHETIC CANNABINOIDS?
 1 https://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids_de (letzter Zugriff 4.9.2020) 
“Synthetic cannabinoids and cathinones dominate the seizures of new psychoactive 
substances.
... The frequency and quantities of new psychoactive substances seized in Europe 
rose sharply until 2015. Since then, this trend seems to have reversed towards 
stabilisation or slow decline, depending on the region. Even so, their overall 
availability remains high. 
… In Europe, seizures of new psychoactive substances are typically dominated by 
synthetic cannabinoids and cathinones, which together accounted for 77 % of all 
seizures reported in 2018 (64 % for the EU Member States). 
… Products containing cannabinoids and cathinones, including herbal smoking 
mixtures and liquids for e-cigarettes, are typically prepared from bulk powders. 
In recent years, there has been a decrease in the number and quantity of powders 
containing synthetic cannabinoids and cathinones seized in the European Union. 
For cannabinoids, this may reflect a decrease in local processing of herbal smoking 
mixtures.” 
(In EMCDDA, Drug Report 2020). 
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WHAT DOES THE EMCDDA SAY?
source: Saferparty.ch
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So-called synthetic cannabinoids have been circulating on the illegal drug market 
in Switzerland since 2008. Originally used as an additive in incense mixtures 
(e.g. “Spice”), they were mainly consumed by experienced consumers (so-called 
“psychonauts”) for its effects. Synthetic cannabinoids cannot be detected in standard 
urine tests, which is why these substances were also consumed by people who have 
to give urine samples regularly.
In 2019, synthetic cannabinoids were tested for the first time as an additive to 
cannabis flowers or hashish in various Swiss drug-checking offers. Since the 
beginning of 2020, inquiries and analyses about synthetic cannabinoids have been 
increasing in the Drug Information Centre (DIZ) of the City of Zurich. The Forensic 
Institute Zurich has also noticed a significant increase in seizures since the end of 
20192.
Due to the limited capacities in the DIZ, as of September 2020, around ten people 
who would like to submit suspicious cannabis samples for analysis have to be 
turned away per week.  Feedback from other drug checking services in Europe and 
the EMCDDA suggest that the increased occurrence of synthetic cannabinoids is a 
phenomenon that has so far been predominantly observed in Switzerland.
STARTING POINT
Table of cannabinoids
1
2 Schläpfer, M.; Bissig, C.; Bogdal, C.: Synthetische Cannabimimetika auf Industriehanf-blüten – ein gefährliches Aufeinandertreffen zweier bekannter Phänomene, in: Kriminalis-tik [07/20].  
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In the first eight months of 2020, the DIZ analysed 91 cannabis samples that were 
suspected of having been treated with synthetic cannabinoids. While leaving their 
samples for the analysis, the clients declared the following: 
 Ǳ 85 sales of “conventional weed” (cannabis flowers with a content 
of over 1% THC)
 Ǳ Five sales of hashish
 Ǳ One sale of “legal weed” with a THC content of less than 1% 
    (“CBD weed”)
83 people stated that they had bought the substance in their private circle (friends, 
etc.). Six people bought the cannabis “on the street”, one person on the Internet and 
one at a party.
Synthetic cannabinoids can only be determined using complex methods such as 
gas chromatography and mass spectrometry. The laboratory analysis of the 91 
submitted samples led to the following results:
Over half of the samples (50) tested positive for synthetic cannabinoids.
 Ǳ 48 samples were «CBD grass» (THC <1%)
 Ǳ One sample had a THC content of over 1%.
 Ǳ One sample had both high levels of CBD and high levels of THC.
The 50 positively tested samples contained between one and five different 
synthetic cannabinoids. 34 samples contained one synthetic cannabinoid ; eight 
samples contained two whilst seven samples contained three different synthetic 
cannabinoids, and one sample contained five different ones. Little is known about 
the interactions and additional risks associated with the mixed consumption of 
varying synthetic cannabinoids. However, it can be assumed that the risks associated 
with consumption increase the more different synthetic cannabinoids. One of the 
NINETY-ONE (91) SUBSTANCE SAMPLES 
SUBMITTED TO THE DIZ AND ANALYSED
ANALYSIS RESULTS: OVER 50% OF THE 
SAMPLES WITH SYNTHETIC CANNABINOIDS
2
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most frequently detected substance (n = 27),5 F-MDMB-PICA, is suspected to be 
responsible for several deaths in Europe and North America4. There is still not 
enough information collected about the mode of action and toxicology of these and 
the other substances analysed (see figure 1).
The various synthetic cannabinoids are only determined qualitatively in the 
laboratory (no quantitative measurements), which is why no statements can be 
made about their potency. 
4 https://www.who.int/medicines/access/controlled-substances/Final_5F-MDMB-PICA.PDF?ua=1 sowie 
   https://www.emcdda.europa.eu/system/files/publica-tions/5483/2017.4963_TDAS17003ENN_PDFWEB.pdf (letzter Zugriff 4.9.2020)  
Figure 1: Synthetic cannabinoids analysed by frequency in the 50 samples of occurrence.
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The users reported to the DIZ after they experienced severe, unfamiliar side effects, 
such as palpitations, extreme inner restlessness, panic attacks, disorientation, 
unconsciousness, hallucinations and unusually strong feelings of intoxication. 
These were felt to be particularly intense, mainly in the first 10 to 30 minutes after 
consumption. Occasionally, clients had to seek emergency medical care due to the 
severe symptoms.
SYMPTOMS AFTER CONSUMPTION4
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Synthetic cannabinoids that are not declared as such can lead to dangerous 
overdoses and/or intense, often harmful side effects. This effect is sometimes 
intensified by the uneven distribution5 of the substance on the flowers, which can 
lead to high concentrations.
In contrast to naturally occurring THC, acute and serious poisoning is common 
with synthetic cannabinoids. Consumption of these can lead to fainting, 
palpitations, high blood pressure, seizures, nausea with vomiting, decreased mental 
performance, confusion, delusions, acute psychoses, a strong desire for further 
consumption (craving) and aggressive and violent behaviour up to a heart attack.
The high potential of synthetic cannabinoids increases the risk of overdosing. In 
addition to their high effectiveness, some synthetic cannabinoids have an incredibly 
long breakdown time for the substance (detectability) in the blood and can lead to a 
prolonged psychoactive effect.
RISK ASSESSMENT5
 Ǳ Get cannabis tested in a drug-checking service if you suspect something is 
wrong with it.
 Ǳ Just ”test“ newly purchased cannabis products the first time you use them (take 
two or three puffs) and then wait 20 minutes. If the effect is unusual, absolutely 
refrain from further consumption!
 Ǳ Avoid mixed consumption! Mixed consumption (also with alcohol or 
medication) is particularly risky because of the unpredictable and as yet 
unknown interactions.
 Ǳ Mix cannabis products well before consumption (use a grinder) to avoid a 
high concentration of possible synthetic cannabinoids on individual flower 
parts. Particular care should be taken with residual material that has fallen 
off the outer flower parts, as it is assumed that it contains a particularly high 
concentration of synthetic cannabinoids.
SAFER USE RULES6
5 Synthetische Cannabinoide werden mit Zerstäubern auf die Blüten aufgetragen, was zu einer ungleichmässigen Verteilung führt.  
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 Ǳ Only a laboratory analysis provides reliable information about the composition 
of cannabis. 
 Ǳ Synthetic cannabinoids cannot be visually recognized. 
 Ǳ The price cannot be an indication for misdeclaration. In the DIZ, consumers 
named an average purchase price of CHF 10/gram (approximately 9.4 Euro/
gram) which corresponds to the market prices for illegal, THC-rich weed.
 Ǳ The assessment that cannabis is a substance with a comparatively low risk of 
overdose has been obsolete since the appearance of synthetic cannabinoids.
 Ǳ In particular, if users are not aware of their consuming a significantly more 
potent substance than assumed (false declaration), there is a high risk of 
overdosing.
 Ǳ More than half of the suspicious samples tested in the DIZ contained one or 
more synthetic cannabinoids. The suspicion was not confirmed with the 
other samples showing that the set and setting can also influence the effect 
experienced when consuming cannabis.
Overall, the current development from the perspective of the DIZ is worrying and 
requires additional measures to reduce harms. The DIZ is therefore expanding its 
range to a total of 10 cannabis sample submissionweekly, as of October 1, 2020. The 
offer is anonymous and free of charge and, in addition to the substance analysis, 
includes a mandatory consultation with a specialist. The results of the cannabis 
drug checks are continuously evaluated and published in a quarterly monitoring 
report on www.saferparty.ch. 
The publication of the next report will be in January 2021.
CONCLUSIONS7
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